AMRX Q2 2021 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$535M+15.2% YoY

Gross Profit

$212M39.7% margin

Operating Income

$67M12.5% margin

Net Income

$15M2.7% margin

EPS (Diluted)

$0.10

QoQ Revenue Growth

+8.5%

Cash Flow

Operating Cash Flow

-$52M

Free Cash Flow

-$60M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$4.0B

Total Liabilities

$3.6B

Stockholders' Equity

$346M

Cash & Equivalents

$278M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$535M	$465M	+15.2%
Gross Profit	$212M	$144M	+47.3%
Operating Income	$67M	$11M	+524.3%
Net Income	$15M	-$12M	+221.1%

Revenue Segments

Generics Segment

$360M67%

Amneal Specialty Pharma Segment

$89M17%

Av K A R E Segment

$86M16%